PATENT CLAIM ANALYSIS

Application Number: 15943112
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "277000"]

Abstract:
The present invention relates to compositions and methods for cancer treatment comprising compounds of Formulae I, II, and III. In some aspects, the invention relates to the treatment of B-cell Lymphoma or other hematopoietic cancers. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as, for example, B-cell lymphoma, using a combination of one or more compounds of Formulae I, II, and III. Combination therapy with, for example, 26S proteasome inhibitors, such as, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formulae I, II, and III. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

Claim (Index 27):
A method of selecting a therapeutic agent for a subject comprising the steps:\n a) obtaining a cancer cell or cellular component thereof from the subject; b) contacting the cancer cell or cellular component with a compound of any one of  claim 1 ,  6 , or  10 ; c) determining whether or not said compound of any one of  claim 1 ,  6 , or  10  induces apoptosis in the cancer cell or triggers an apoptotic signal in the cellular component to produce a control Mcl-1 response; d) contacting the cancer cell or cellular component with the agent e) determining whether or not the agent induces apoptosis in the cancer cell or triggers an apoptotic signal in the cellular component to produce a test Mcl-1 response; and f) comparing the test Mcl-1 response to the control Mcl-1 response wherein a similarity of the test Mcl-1 response compared to the control Mcl-1 response indicates that the agent is therapeutic for the subject.

Metadata:
- Claim Count in Document: 12.0
- Percentile: 91.0
- Lexical Diversity: 2.35616
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15792095', '14003733', '14700875', '14624263', '12760380']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7888212872736282
- 35 USC 102 Novelty (BERT): 0.5408596434918715
- Combined Prediction Score: 0.7640251228954525
- Mean Citation Score: 348.29576799999984
- Max Citation Score: 387.6464
- Similarity Product: 262.12463662786485

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test